COPD and comorbidities in the
Republic of Moldova

Siafakas, Nikolaos; Corlateanu, Alexandru; Rusu, Doina; Corlateanu, Olga; Serghei, Covantev; Scutaru, Eugenia; Botnaru, Victor

doi:10.14744/ejop_78_21

COPD and comorbidities in the Republic of Moldova

Alexandru Corlateanu, (Division of Pneumology and Allergology, Department of Internal Medicine, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldova)

Serghei Covantsev, (Division of Pneumology and Allergology, Department of Internal Medicine, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldovaacy “Nicolae Testemitanu”, Chisinau, Moldova)

Eugenia Scutaru, (Division of Pneumology and Allergology, Department of Internal Medicine, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldova,)

Doina Rusu, (Division of Pneumology and Allergology, Department of Internal Medicine, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldova)

Victor Botnaru, (Division of Pneumology and Allergology, Department of Internal Medicine, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldova)

Olga Corlateanu, (Department of Internal Medicine, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldova)

Nikolaos Siafakas (Department of Thoracic Medicine, University General Hospital, Crete, Greece)

Eurasian Journal of Pulmonology

5 0

Yıl: 2022 Cilt: 24 Sayı: 1 Sayfa Aralığı: 9 - 17 Metin Dili: İngilizce DOI: 10.14744/ejop_78_21 İndeks Tarihi: 21-06-2022

COPD and comorbidities in the Republic of Moldova

Öz:

BACKGROUND AND AIM: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide, and the majority of patients have at least one comorbid condition of clinical significance. Therefore, we studied its prevalence and implication based on experience from the Republic of Moldova. METHODS: The study was a prospective cohort study that included 435 patients with COPD from 2015 to 2017. RESULTS: We found heart failure in 38.62% of the patients, hypertension in 50.11%, coronary artery disease in 23.45%, diabetes mellitus in 10.11%, renal failure in 1.15%, rheumatoid arthritis in 3.22%, depression in 4.83%, cognitive impairment in 4.37%, obesity in 29.89%, and cachexia in 3.22%. Only 24.65% of patients did not have comorbidities. One comorbidity was found in 23.73%, two in 24.19%, three or more in 27.42%. The Charlson comorbidity index (CCI) had a medium negative correlation with the 6-minute walking test (r=–0.37, p<0.001) and a weak correlation with the rate of exacerbations (r=0.17, p=0.016). CCI had a strong correlation with ADO (age, dyspnea and airflow obstruction) (r=0.75, p<0.001); moderate with BODE (body mass index, airflow obstruction, dyspnea, and exercise) (r=0.3, p<0.001); and weak with BODEx (body mass index, airflow obstruction, dyspnea, and exacerbations), CODEX (comorbidity, obstruc- tion, dyspnea, and previous severe exacerbations), and DOSE (dyspnea, obstruction, smoking, and exacerbation). CCI had a medium correlation with St. George’s Respiratory Questionnaire (SGRQ) activity (r=0.36, p<0.001), impact (r=0.34, p<0.001), and total (r=0.37, p<0.001) scores, and the overall quality of life assessed by SGRQ and Clinical COPD Questionnaire. CONCLUSIONS: Patients with COPD require a multidisciplinary approach to assess and manage a variety of conditions, which influence the evolution and prognosis of COPD. Patients often have one or two comorbidities of clinical significance, and they are predominantly cardiovascular and meta- bolic. Patients with comorbidities tend to have a poorer health-related quality of life. Comorbidities canc. Patients with comorbidities tend to have a poorer health-related quality of life. Comorbidities can be assessed by multidimensional indexes such as ADO and BODE.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, manage- ment, and prevention of chronic obstructive lung disease 2017 Report. GOLD executive summary. Am J Respir Crit Care Med 2017;195:557–82.
2. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: A systematic analysis for the global burden of disease study 2015. Lancet Respir Med 2017;5:691–706.
3. Chen W, FitzGerald JM, Sin DD, Sadatsafavi M. Excess economic burden of comorbidities in COPD: A 15-year population-based study. Eur Respir J 2017;50:1700393.
4. Negewo NA, Gibson PG, Wark PA, Simpson JL, McDonald VM. Treatment burden, clinical outcomes, and comorbidities in COPD: An examination of the utility of medication regimen complexity index in COPD. Int J Chron Obstruct Pulmon Dis 2017;12:2929–42.
5. Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respir Investig 2016;54:387–96.
6. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different co- morbidities in COPD patients by gender and GOLD stage. Mul- tidiscip Respir Med 2015;10:24.
7. Rogliani P, Brusasco V, Fabbri L, Ungar A, Muscianisi E, Barisone I, et al. Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary dis- ease. Expert Rev Respir Med 2018;12:103–12.
8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319–38.
9. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948–68.
10. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Men- dez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary dis- ease. N Engl J Med 2004;350:1005–12.
11. Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: Two indepen- dent risk factors for death in male COPD patients. Respir Med 2009;103:692–9.
12. Sundh J, Janson C, Lisspers K, Ställberg B, Montgomery S. The dys- pnoea, obstruction, smoking, exacerbation (DOSE) index is predic- tive of mortality in COPD. Prim Care Respir J 2012;21:295–301.
13. Puhan MA, Hansel NN, Sobradillo P, Enright P, Lange P, Hickson D, et al. Large-scale international validation of the ADO index in subjects with COPD: An individual subject data analysis of 10 co- horts. BMJ Open 2012;2:e002152.
14. Almagro P, Soriano JB, Cabrera FJ, Boixeda R, Alonso-Ortiz MB, Barreiro B, et al. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: The CODEX index. Chest 2014;145:972–80.
15. Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and chronic obstructive pulmonary disease: Prevalence, influ- ence on outcomes, and management. Semin Respir Crit Care Med 2015;36:575–91.
16. Angelos A, Charalambos V, Nikolaos I, Athanasios A, Konstantinos A, Christodoulos S. Cardiovascular comorbidities of COPD: When do they occur and howare they managed? Curr Respir Med Rev 2013;9:384–91.
17. Jo YS, Choi SM, Lee J, Park YS, Lee SM, Yim JJ, et al. The relation- ship between chronic obstructive pulmonary disease and comor- bidities: A cross-sectional study using data from KNHANES 2010- 2012. Respir Med 2015;109:96–104.
18. Haraguchi M, Nakamura H, Sasaki M, Miyazaki M, Chubachi S, Takahashi S, et al. Determinants of chronic obstructive pulmonary disease severity in the late-elderly differ from those in younger pa- tients. BMC Res Notes 2016;9:7.
19. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comor- bidities in COPD. Int J Chron Obstruct Pulmon Dis 2015;10:95–109.
20. Fumagalli G, Fabiani F, Forte S, Napolitano M, Balzano G, Bonini M, et al. INDACO project: COPD and link between comorbidities, lung function and inhalation therapy. Multidiscip Respir Med 2015;10:4.
21. Battaglia S, Basile M, Scichilone N, Bellia V. Prevalence of co-mor- bidities and severity of COPD. COPD 2015;12:390–4.
22. Higashimoto Y, Yamagata T, Maeda K, Honda N, Sano A, Nishiyama O, et al. Influence of comorbidities on the efficacy of pulmonary rehabilitation in patients with chronic obstructive pul- monary disease. Geriatr Gerontol Int 2016;16:934–41.
23. Park HJ, Leem AY, Lee SH, Song JH, Park MS, Kim YS, et al. Comor- bidities in obstructive lung disease in Korea: Data from the fourth and fifth Korean National Health and Nutrition Examination Sur- vey. Int J Chron Obstruct Pulmon Dis 2015;10:1571–82.
24. Straburzyńska-Migaj E, Kałużna-Oleksy M, Maggioni AP, Grajek S, Opolski G, Ponikowski P, et al. Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) - Polish popula- tion. Arch Med Sci 2015;11:743–50.
25. Valk MJ, Broekhuizen BD, Mosterd A, Zuithoff NP, Hoes AW, Rut- ten FH. COPD in patients with stable heart failure in the primary care setting. Int J Chron Obstruct Pulmon Dis 2015;10:1219–24.
26. Rogliani P, Calzetta L, Segreti A, Barrile A, Cazzola M. Diabetes mellitus among outpatients with COPD attending a university hos- pital. Acta Diabetol 2014;51:933–40.
27. Ajmera M, Shen C, Sambamoorthi U. Concomitant medication use and New-Onset diabetes among medicaid beneficiaries with chronic obstructive pulmonary disease. Popul Health Manag 2017;20:224–32.
28. Lambert AA, Putcha N, Drummond MB, Boriek AM, Hanania NA, Kim V, et al. Obesity is associated with increased morbidity in moderate to severe COPD. Chest 2017;151:68–77.
29. Wei YF, Tsai YH, Wang CC, Kuo PH. Impact of overweight and obesity on acute exacerbations of COPD - subgroup analysis of the Taiwan obstructive lung disease cohort. Int J Chron Obstruct Pul- mon Dis 2017;12:2723–9.
30. Incalzi RA, Corsonello A, Pedone C, Battaglia S, Paglino G, Bellia V. Chronic renal failure: A neglected comorbidity of COPD. Chest 2010;137:831–7.
31. Yoshizawa T, Okada K, Furuichi S, Ishiguro T, Yoshizawa A, Aka- hoshi T, et al. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: Assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels. Int J Chron Obstruct Pulmon Dis 2015;10:1283–9.
32. Ohayon MM. Chronic obstructive pulmonary disease and its asso- ciation with sleep and mental disorders in the general population. J Psychiatr Res 2014;54:79–84.
33. Mehta JR, Ratnani IJ, Dave JD, Panchal BN, Patel AK, Vala AU. Association of psychiatric co-morbidities and quality of life with severity of chronic obstructive pulmonary disease. East Asian Arch Psychiatry 2014;24:148–55.
34. Singh B, Parsaik AK, Mielke MM, Roberts RO, Scanlon PD, Geda YE, et al. Chronic obstructive pulmonary disease and association with mild cognitive impairment: The mayo clinic study of aging. Mayo Clin Proc 2013;88:1222–30.
35. Grant I, Heaton RK, McSweeny AJ, Adams KM, Timms RM. Neu- ropsychologic findings in hypoxemic chronic obstructive pul- monary disease. Arch Intern Med 1982;142:1470–6.
36. Barr RG, Celli BR, Mannino DM, Petty T, Rennard SI, Sciurba FC, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009;122:348–55.
37. Fumagalli G, Fabiani F, Forte S, Napolitano M, Marinelli P, Palange P, et al. INDACO project: A pilot study on incidence of comorbidi- ties in COPD patients referred to pneumology units. Multidiscip Respir Med 2013;8:28.
38. Garcia-Olmos L, Alberquilla A, Ayala V, Garcia-Sagredo P, Morales L, Carmona M, et al. Comorbidity in patients with chronic obstruc- tive pulmonary disease in family practice: A cross sectional study. BMC Fam Pract 2013;14:11.
39. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155–61.
40. Westerik JAM, Metting EI, van Boven JFM, Tiersma W, Kocks JWH, Schermer TR. Associations between chronic comorbidity and ex- acerbation risk in primary care patients with COPD. Respir Res 2017;18:31.
41. Greulich T, Weist BJD, Koczulla AR, Janciauskiene S, Klemmer A, Lux W, et al. Prevalence of comorbidities in COPD patients by dis- ease severity in a German population. Respir Med 2017;132:132–8.
42. Miyazaki M, Nakamura H, Chubachi S, Sasaki M, Haraguchi M, Yoshida S, et al. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res 2014;15:13.
43. Sundh J, Johansson G, Larsson K, Linden A, Lofdahl CG, Janson C, et al. Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units. Int J Chron Obstruct Pulmon Dis 2015;10:173– 83.
44. Lee H, Jhun BW, Cho J, Yoo KH, Lee JH, Kim DK, et al. Different impacts of respiratory symptoms and comorbidities on COPD-spe- cific health-related quality of life by COPD severity. Int J Chron Ob- struct Pulmon Dis 2017;12:3301–10.
45. Corlateanu A, Botnaru V, Covantev S, Dumitru S, Siafakas N. Predicting health-related quality of life in patients with chronic obstructive pulmonary disease: The impact of age. Respiration 2016;92:229–34

APA	Corlateanu A, Serghei C, Scutaru E, Rusu D, Botnaru V, Corlateanu O, Siafakas N (2022). COPD and comorbidities in the Republic of Moldova. , 9 - 17. 10.14744/ejop_78_21
Chicago	Corlateanu Alexandru,Serghei Covantev,Scutaru Eugenia,Rusu Doina,Botnaru Victor,Corlateanu Olga,Siafakas Nikolaos COPD and comorbidities in the Republic of Moldova. (2022): 9 - 17. 10.14744/ejop_78_21
MLA	Corlateanu Alexandru,Serghei Covantev,Scutaru Eugenia,Rusu Doina,Botnaru Victor,Corlateanu Olga,Siafakas Nikolaos COPD and comorbidities in the Republic of Moldova. , 2022, ss.9 - 17. 10.14744/ejop_78_21
AMA	Corlateanu A,Serghei C,Scutaru E,Rusu D,Botnaru V,Corlateanu O,Siafakas N COPD and comorbidities in the Republic of Moldova. . 2022; 9 - 17. 10.14744/ejop_78_21
Vancouver	Corlateanu A,Serghei C,Scutaru E,Rusu D,Botnaru V,Corlateanu O,Siafakas N COPD and comorbidities in the Republic of Moldova. . 2022; 9 - 17. 10.14744/ejop_78_21
IEEE	Corlateanu A,Serghei C,Scutaru E,Rusu D,Botnaru V,Corlateanu O,Siafakas N "COPD and comorbidities in the Republic of Moldova." , ss.9 - 17, 2022. 10.14744/ejop_78_21
ISNAD	Corlateanu, Alexandru vd. "COPD and comorbidities in the Republic of Moldova". (2022), 9-17. https://doi.org/10.14744/ejop_78_21

APA	Corlateanu A, Serghei C, Scutaru E, Rusu D, Botnaru V, Corlateanu O, Siafakas N (2022). COPD and comorbidities in the Republic of Moldova. Eurasian Journal of Pulmonology, 24(1), 9 - 17. 10.14744/ejop_78_21
Chicago	Corlateanu Alexandru,Serghei Covantev,Scutaru Eugenia,Rusu Doina,Botnaru Victor,Corlateanu Olga,Siafakas Nikolaos COPD and comorbidities in the Republic of Moldova. Eurasian Journal of Pulmonology 24, no.1 (2022): 9 - 17. 10.14744/ejop_78_21
MLA	Corlateanu Alexandru,Serghei Covantev,Scutaru Eugenia,Rusu Doina,Botnaru Victor,Corlateanu Olga,Siafakas Nikolaos COPD and comorbidities in the Republic of Moldova. Eurasian Journal of Pulmonology, vol.24, no.1, 2022, ss.9 - 17. 10.14744/ejop_78_21
AMA	Corlateanu A,Serghei C,Scutaru E,Rusu D,Botnaru V,Corlateanu O,Siafakas N COPD and comorbidities in the Republic of Moldova. Eurasian Journal of Pulmonology. 2022; 24(1): 9 - 17. 10.14744/ejop_78_21
Vancouver	Corlateanu A,Serghei C,Scutaru E,Rusu D,Botnaru V,Corlateanu O,Siafakas N COPD and comorbidities in the Republic of Moldova. Eurasian Journal of Pulmonology. 2022; 24(1): 9 - 17. 10.14744/ejop_78_21
IEEE	Corlateanu A,Serghei C,Scutaru E,Rusu D,Botnaru V,Corlateanu O,Siafakas N "COPD and comorbidities in the Republic of Moldova." Eurasian Journal of Pulmonology, 24, ss.9 - 17, 2022. 10.14744/ejop_78_21
ISNAD	Corlateanu, Alexandru vd. "COPD and comorbidities in the Republic of Moldova". Eurasian Journal of Pulmonology 24/1 (2022), 9-17. https://doi.org/10.14744/ejop_78_21